Science and Technology

Archive | news

February 15, 2017

X-Chem Expands Collaboration with Janssen in Inflammatory Diseases

WALTHAM, Mass. – February 15, 2017 – X-Chem, Inc. (X-Chem) announced today that it has expanded its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new drug leads for the treatment of inflammatory disease. The multi-target expansion builds on the parties’ existing discovery and license partnership, […]

Continue Reading
December 20, 2016

X-Chem Announces Multi-Target Drug Discovery Collaboration with Taiho Pharmaceutical using DEX™ Technology

WALTHAM, Mass. – December 20, 2016 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced that it entered into a multi-target drug discovery collaboration with Taiho Pharmaceutical Co. Ltd. This collaboration will grant Taiho access to X-Chem’s DEX™ […]

Continue Reading
July 26, 2016

X-Chem and AbbVie Enter into Multi-Target Drug Discovery Partnership

WALTHAM, Mass. – July 26, 2016 – X-Chem, Inc., a privately held biotechnology company applying its cutting-edge lead discovery capabilities to the generation of novel small molecule therapeutics, today announced a multi-target drug discovery agreement with AbbVie. The collaboration is focused on the discovery and development of novel treatments for diseases in oncology and immunology. […]

Continue Reading
July 12, 2016

X-Chem and Bayer Expand Drug Discovery Collaboration to Discover Novel Medicines

WALTHAM, Mass. – July 12, 2016 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, and Bayer have entered into an expanded global drug discovery collaboration across multiple therapeutic areas and target classes. The new agreement extends Bayer’s access to […]

Continue Reading
April 27, 2016

X-Chem Announces Achievement of Milestone in Alexion Collaboration

WALTHAM, Mass. – April 27 2016 – X-Chem, Inc. (X-Chem), a privately held biotechnology company utilizing its industry-leading DNA-Encoded X-Chem (DEX™) drug discovery platform for the identification of first-in-class small molecule therapeutics, today announced that it has achieved a milestone in its drug discovery collaboration with Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), triggering a payment to […]

Continue Reading
March 30, 2016

X-Chem Announces License with Janssen for Protein:Protein Inhibitor Program in Inflammatory Disease

WALTHAM, Mass. – March 30, 2016 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative DNA-Encoded X-Chem (DEX™) drug discovery platform to generate novel therapeutics, today announced that a licensing option with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has been exercised for a protein inhibitor […]

Continue Reading
January 6, 2016

X-Chem Collaborates with Sanofi on the Discovery of Lead Molecules against Multiple Challenging Targets

WALTHAM, Mass. – January 6 , 2015 – X-Chem, Inc., a privately held biotechnology company applying its cutting-edge lead discovery capabilities to the generation of novel small molecule therapeutics, announced a multi-target collaboration with Sanofi. The collaboration is focused on the potential development of several programs for treatments in therapeutic areas such as oncology, rare […]

Continue Reading
March 31, 2015

X-Chem and Navitor Pharmaceuticals Enter into License Agreement on Novel Small Molecules Targeting mTORC1 Activation

WALTHAM & CAMBRIDGE, Mass. – March 30, 2015 –X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, today announced that Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling, exercised its option to obtain an exclusive […]

Continue Reading